NCT03735849View on ClinicalTrials.gov

Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 18, 2019

Primary Completion Date

December 21, 2020

Study Completion Date

December 21, 2020

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC07-523LS

Administered by intravenous (IV) infusion

Trial Locations (2)

02115-6110

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

98109-1024

Seattle Vaccine and Prevention CRS, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03735849 - Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants | Biotech Hunter | Biotech Hunter